litlas
Log inCreate account

Thomas J. Schall

Active 1987–2024

91
Papers
29,998
Citations
84
h-index
90
i10-index

Citations

Citations per year for Thomas J. Schall1979: 2 citations1981: 1 citations1989: 12 citations1990: 23 citations1991: 50 citations1992: 62 citations1993: 123 citations1994: 212 citations1995: 229 citations1996: 426 citations1997: 585 citations1998: 770 citations1999: 613 citations2000: 535 citations2001: 423 citations2002: 360 citations2003: 300 citations2004: 271 citations2005: 205 citations2006: 174 citations2007: 193 citations2008: 210 citations2009: 190 citations2010: 211 citations2011: 219 citations2012: 197 citations2013: 209 citations2014: 208 citations2015: 155 citations2016: 115 citations2017: 144 citations2018: 126 citations2019: 447 citations2020: 599 citations2021: 545 citations2022: 451 citations2023: 403 citations2024: 547 citations2025: 245 citations2026: 2 citations1980: no citations, so this year is not shown1982–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,590 citing papers, 35.2% of this breakdownUnited Kingdom: 742 citing papers, 7.3% of this breakdownChina: 710 citing papers, 6.9% of this breakdownGermany: 690 citing papers, 6.8% of this breakdownJapan: 509 citing papers, 5% of this breakdownFrance: 429 citing papers, 4.2% of this breakdownItaly: 409 citing papers, 4% of this breakdownCanada: 344 citing papers, 3.4% of this breakdownSwitzerland: 269 citing papers, 2.6% of this breakdownNetherlands: 262 citing papers, 2.6% of this breakdownAustralia: 219 citing papers, 2.1% of this breakdownSpain: 198 citing papers, 1.9% of this breakdown
0%35.2%Other 18%

Institutions

Fields

  • Medicine54.2%
  • Immunology and Microbiology29.8%
  • Biochemistry, Genetics and Molecular Biology9.9%
  • Neuroscience4.3%
  • Agricultural and Biological Sciences0.4%
  • Pharmacology, Toxicology and Pharmaceutics0.2%
  • Other1.2%

Topics

  • Chemokine receptors and signaling9.5%
  • Immune Cell Function and Interaction5.6%
  • Immunotherapy and Immune Responses4.7%
  • T-cell and B-cell Immunology4.4%
  • HIV Research and Treatment4.1%
  • Cell Adhesion Molecules Research3%
  • Other68.7%

Coauthors

All papers

Open in search
  1. Avacopan for the Treatment of ANCA-Associated Vasculitis

    Authors: David Jayne, Peter A. Merkel, Thomas J. Schall, Pirow Bekker - New England Journal of Medicine 2021 cited by 969

  2. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas

    Authors: Joseph Flores‐Toro, Defang Luo, Adithya Gopinath, Matthew R. Sarkisian, James J. Campbell, Israel Charo, Rajinder Singh, Thomas J. Schall, Meenal Datta, Rakesh K. Jain, Duane A. Mitchell, Jeffrey K. Harrison - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 332

  3. A new class of membrane-bound chemokine with a CX3C motif

    Authors: J. Fernando Bazán, Kevin B. Bacon, Gary Hardiman, Wei Wang, Ken S Soo, Dévora L. Rossi, David R. Greaves, Albert Zlotnik, Thomas J. Schall - Nature 1997 cited by 2,016

  4. Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion

    Authors: Toshio Imai, Kunio Hieshima, Christopher A. Haskell, Masataka Baba, Morio Nagira, Miyuki Nishimura, Mayumi Kakizaki, Shin Takagi, Hisayuki Nomiyama, Thomas J. Schall, Osamu Yoshie - Cell 1997 cited by 1,476

  5. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

    Authors: David Jayne, Annette Bruchfeld, Lorraine Harper, Matthias Schaier, Michael Venning, Patrick Hamilton, Volker Burst, Franziska Grundmann, Michel Jadoul, István Szombati, Vladimı́r Tesař, Mårten Segelmark, Antonia Potarca, Thomas J. Schall, Pirow Bekker, for the CLEAR Study Group - Journal of the American Society of Nephrology 2017 cited by 600

  6. Cancer associated fibroblast FAK regulates malignant cell metabolism

    Authors: Fevzi Demircioglu, Jun Wang, Juliana Candido, Ana S.H. Costa, Pedro Casado, Beatriz de Luxán‐Delgado, Louise E. Reynolds, Jesús Gómez-Escudero, Emma Newport, Vinothini Rajeeve, Ann‐Marie Baker, Marina Roy-Luzarraga, Trevor A. Graham, Julie Foster, Yu Wang, James J. Campbell, Rajinder Singh, Penglie Zhang, Thomas J. Schall, Frances R. Balkwill, Jane Sosabowski, Pedro R. Cutillas, Christian Frezza, Patricia Sancho, Kairbaan Hodivala‐Dilke - Nature Communications 2020 cited by 167

  7. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development

    Authors: Jennifer M. Burns, Bretton C. Summers, Yu Wang, Anita Melikian, Rob Berahovich, Zhenhua Miao, Mark E.T. Penfold, Mary Jean Sunshine, Dan R. Littman, Calvin J. Kuo, Kevin Wei, Brian E. McMaster, K Wright, Maureen Howard, Thomas J. Schall - The Journal of Experimental Medicine 2006 cited by 1,264

  8. C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN

    Authors: Hong Xiao, Daniel J. Dairaghi, Jay P. Powers, Linda Ertl, Trageen Baumgart, Yu Wang, Lisa Seitz, Mark E.T. Penfold, Lin Gan, Peiqi Hu, Bao Lu, Norma P. Gerard, Craig Gérard, Thomas J. Schall, Juan C. Jaén, Ronald J. Falk, J. Charles Jennette - Journal of the American Society of Nephrology 2013 cited by 356

  9. Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias

    Authors: Yu‐Chen Yen, Christopher T. Schafer, Martin Gustavsson, S.A. Eberle, Pawel K. Dominik, Dawid Deneka, Penglie Zhang, Thomas J. Schall, Anthony A. Kossiakoff, J.J.G. Tesmer, Tracy M. Handel - Science Advances 2022 cited by 85

  10. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial

    Authors: Dick de Zeeuw, Pirow Bekker, Elena Henkel, C. Hasslacher, Ioanna Gouni-Berthold, Heidrun Mehling, Antonia Potarca, Vladimı́r Tesař, Hiddo J.L. Heerspink, Thomas J. Schall - The Lancet Diabetes & Endocrinology 2015 cited by 274

  11. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

    Authors: Frank B. Cortazar, John L. Niles, David Jayne, Peter A. Merkel, Annette Bruchfeld, Huibin Yue, Thomas J. Schall, Pirow Bekker, Chen Au Peh, Aron Chakera, Bruce A. Cooper, Jadadeesh Kurtkoti, Daman Langguth, Vicki Levidiotis, G. Luxton, Peter F. Mount, David W. Mudge, Euan Noble, R. Phoon, Dwarakanathan Ranganathan, A. Ritchie, Jessica Ryan, M. Suranyi, Alexander R. Rosenkranz, K. Lhotta, Andreas Kronbichler, Nathalie Demoulin, C. Bovy, R. Hellemans, Jean‐Michel Hougardy, Ben Sprangers, Katherine D. Wissing, Christian Pagnoux, S. Barbour, Soumeya Brachemi, S. Cournoyer, Louis Girard, Louis‐Philippe Laurin, Patrick Liang, David Philibert, Michael Walsh, Vladimı́r Tesař, R. Becvar, P. Horak, Ivan Rychlík, Wladimir Szpirt, Hans Dieperink, Jon Waarst Gregersen, Per Ivarsen, Elizabeth Krarup, Cecilie Lyngsøe, Claire Rigothier, Jean‐François Augusto, Alexandre Bélot, Dominique Chauveau, Divi Cornec, Noémie Jourde‐Chiche, M. Ficheux, Alexandre Karras, Armelle Klein, F. Maurier, Rafik Mesbah, Olivier Moranne, A. Néel, T. Quéméneur, David Saadoun, Benjamin Terrier, Philippe Zaoui, Matthias Schaier, Urs Benck, Raoul Bergner, Matthias H. Busch, Jürgen Floege, Franziska Grundmann, Hermann Haller, Marion Haubitz, B. Hellmich, Jörg Henes, Bernd Hohenstein, C. Hugo, Christof Iking‐Konert, Fabian Arndt, Torsten Kubacki, Ina Kötter, Peter Lamprecht, Tom H. Lindner, Jan Halbritter, H. Mehling, Ulf Schönermarck, Nils Venhoff, Volker Vielhauer, Oliver Witzke, István Szombati, G Szücs, Giacomo Garibotto, Federico Alberici, Enrico Brunetta, Lorenzo Dagna, Salvatore De Vita, Giacomo Emmi and 151 more - Kidney International Reports 2023 cited by 85

  12. Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

    Authors: Peter A. Merkel, John L. Niles, Richard Jimenez, Robert Spiera, Brad H. Rovin, Andrew S. Bomback, Christian Pagnoux, Antonia Potarca, Thomas J. Schall, Pirow Bekker, for the CLASSIC Investigators - ACR Open Rheumatology 2020 cited by 121

  13. Identification of a major co-receptor for primary isolates of HIV-1

    Authors: Hongkui Deng, Rong Liu, Wilfried Ellmeier, Sunny Choe, Derya Unutmaz, Michael Burkhart, P Di Marzio, Shoshana Marmon, Richard E. Sutton, Connor Hill, Craig B. Davis, Stephen C. Peiper, Thomas J. Schall, Dan R. Littman, Nathaniel R. Landau - Nature 1996 cited by 3,670

  14. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

    Authors: Pirow Bekker, Daniel J. Dairaghi, Lisa Seitz, Manmohan R. Leleti, Yu Wang, Linda Ertl, Trageen Baumgart, Sarah Shugarts, Lisa Lohr, Ton Dang, Shichang Miao, Yibin Zeng, Pingchen Fan, Penglie Zhang, Daniel E. Johnson, Jay P. Powers, Juan C. Jaén, Israel Charo, Thomas J. Schall - PLoS ONE 2016 cited by 150

  15. Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells

    Authors: Ping‐Pui Wong, José M. Muñoz‐Félix, Maruan Hijazi, Hyo-Jin Kim, Stephen D. Robinson, Beatriz de Luxán‐Delgado, Irene Rodríguez‐Hernández, Óscar Maiques, Ya-Ming Meng, Qiong Meng, Natalia Bodrug, Matthew Dukinfield, Louise E. Reynolds, George Elia, Andrew Clear, Catherine Harwood, Yu Wang, James J. Campbell, Rajinder Singh, Penglie Zhang, Thomas J. Schall, Kylie P. Matchett, Neil C. Henderson, Peter W. Szlosarek, Sally A. Dreger, Sally Smith, J. Louise Jones, John G. Gribben, Pedro R. Cutillas, Pascal Meier, Victoria Sanz‐Moreno, Kairbaan Hodivala‐Dilke - Cell 2020 cited by 111

  16. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES

    Authors: Thomas J. Schall, Kevin B. Bacon, Karen Toy, David V. Goeddel - Nature 1990 cited by 1,406

  17. Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells

    Authors: İhsan Ekin Demir, Kristina Kujundzic, Paulo L. Pfitzinger, Ömer Cemil Saricaoglu, Steffen Teller, Timo Kehl, Carmen Mota Reyes, Linda Ertl, Zhenhua Miao, Thomas J. Schall, Elke Tieftrunk, Bernhard Haller, Kalliope N. Diakopoulos, Magdalena U. Kurkowski, Marina Lesina, Achim Krüger, Hana Algül, Helmut Friess, Güralp O. Ceyhan - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 cited by 86

  18. Overcoming hurdles in developing successful drugs targeting chemokine receptors

    Authors: Thomas J. Schall, Amanda E. I. Proudfoot - Nature reviews. Immunology 2011 cited by 324

  19. Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.

    Authors: David C. Linehan, Marcus Smith Noel, Aram F. Hezel, Andrea Wang‐Gillam, Ferry A.L.M. Eskens, Stefan Sleijfer, Ingrid M.E. Desar, Frans Erdkamp, Johanna W. Wilmink, J. Nathaniel Diehl, Antonia Potarca, Niky Zhao, Shichang Miao, Jun Deng, Jan Hillson, Pirow Bekker, Thomas J. Schall, Rajinder Singh - Journal of Clinical Oncology 2018 cited by 92

  20. Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease

    Authors: Matthew J. Walters, Yu Wang, Nicholas Lai, Trageen Baumgart, Bin Zhao, Daniel J. Dairaghi, Pirow Bekker, Linda Ertl, Mark E.T. Penfold, Juan C. Jaén, Satish Keshav, Emily Wendt, Andrew M. K. Pennell, S Ungashe, Zheng Wei, John Joseph Wright, Thomas J. Schall - Journal of Pharmacology and Experimental Therapeutics 2010 cited by 159

  21. Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial

    Authors: Paul P. Tak, Andra Bălănescu, Vira Tseluyko, S. Bojin, Edit Drescher, Dan Dairaghi, Shichang Miao, Vittorio Marchesin, Juan C. Jaén, Thomas J. Schall, Pirow Bekker - Annals of the Rheumatic Diseases 2012 cited by 99

  22. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease

    Authors: Daniel J. Dairaghi, Babatunde O. Oyajobi, Anjana Gupta, Brandon McCluskey, Shichang Miao, Jay P. Powers, Lisa Seitz, Yu Wang, Yibin Zeng, Penglie Zhang, Thomas J. Schall, Juan C. Jaén - Blood 2012 cited by 86

  23. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature

    Authors: Zhenhua Miao, Kathryn E. Luker, Bretton C. Summers, Rob Berahovich, Mahaveer S. Bhojani, Alnawaz Rehemtulla, Celina G. Kleer, Jeffrey J. Essner, Aidas Nasevicius, Gary D. Luker, Maureen Howard, Thomas J. Schall - National Academy of Sciences, Proceedings of the National Academy of Sciences 2007 cited by 532

  24. Proteolytic Activation of Alternative CCR1 Ligands in Inflammation

    Authors: Robert Berahovich, Zhenhua Miao, Yu Wang, Brett A. Premack, Maureen Howard, Thomas J. Schall - The Journal of Immunology 2005 cited by 180